Health Research at a Crossroads – Are Public-Private Partnerships the Way Forward?
European Parliament, Brussels – Room PHS P7C050
13 November 2012 – 17:00–20:00

16:00 - 17:00  Registration
17:00 – 18:00  Introducing IMI

Welcome and introduction
Amalia Sartori MEP

IMI – the story so far
Ruxandra Draghia-Akli, Director, DG Research & Innovation, European Commission

IMI’s added value to the pharmaceutical industry
Roch Doliveux, Chief Executive Officer, UCB & Chair of the IMI Governing Board

18:00 - 18:20  Break
18:20 – 20:00  Panel discussion

Health research is at a crossroads. Developing new drugs for the many diseases and conditions that still lack a cure or effective treatment is proving extremely difficult, leading some pharmaceutical companies to give up on entire disease areas. Meanwhile, budgets for drug research and development are tighter than ever. Are public-private partnerships (PPPs) the way forward? Or would other models offer a better solution?

Moderator
Andrew Jack, Journalist, Financial Times

Panellists
Michel Goldman, Executive Director, IMI
Ruxandra Draghia-Akli, Director, DG Research & Innovation, European Commission
Magda Chlebus, Director, EFPIA
Mary Baker, President, European Brain Council
Rolf-Detlef Treede, Chair of Neurophysiology, University of Heidelberg
Tine Bryan Stensbøl, Divisional Director, Synaptic Transmission Research, Lundbeck
Hans-Georg Eichler, Senior Medical Officer, European Medicines Agency
Scott Wagers, Chief Executive Officer, BioSci Consulting

20:00  End of meeting
20:00  Networking reception

This event is kindly hosted by Ms Amalia Sartori MEP